Back to search

Article

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization

2022-06-16

Abstract excerpt

<h4>ABSTRACT</h4> Sclerostin inhibition is a new therapeutic approach for increasing bone mineral density (BMD) but its cardiovascular safety is unclear. We conducted a genome-wide association study (GWAS) meta-analysis of circulating sclerostin in 33,961 Europeans followed by Mendelian randomization (MR) to estimate the causal effects of sclerostin on 15 atherosclerosis-related diseases and risk factors. GWAS met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
326c5da0-e6a3-560a-82a3-49c5436031a7
DOI
10.1101/2022.06.13.22275915
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationDOI 10.1101/2022.06.13.22275915
Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity
The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular diseaseSemantic proximity
Lifelong genetically lowered sclerostin and risk of cardiovascular diseaseSemantic proximity
Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.Semantic proximity
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.Semantic proximity
Sclerostin and Cardiovascular DiseaseSemantic proximity
A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibition.Semantic proximity
A novel and efficient machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibitionSemantic proximity
Role of Sclerostin in Cardiovascular SystemSemantic proximity
Effect of genetically proxied plasma sclerostin levels on the risk of ischemic stroke: A drug-target Mendelian randomization study.Semantic proximity
Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in HumansSemantic proximity
Unraveling the Genetic Links Between Plasma Lipidome and Ankylosing Spondylitis: Insights from a Two-Sample Mendelian Randomization ApproachSemantic proximity
Select a neighboring publication to make it the new centre.